Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
125
datasets available to search
ShareScore release 0.9.0
Dataset results
125 results for “Relapsing-remitting multiple sclerosis”
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT01490840. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
ClinicalTrials.gov study NCT00871780. IPD Sharing: Not stated. Countries: 6. Publications: 1.
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compar
ClinicalTrials.gov study NCT01067521. IPD Sharing: Not stated. Countries: 17. Publications: 1.
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT00676715. IPD Sharing: Not stated. Countries: 18. Publications: 1.
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT00451451. IPD Sharing: Not stated. Countries: 28. Publications: 10.
Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)
ClinicalTrials.gov study NCT02493049. IPD Sharing: NO. Countries: 1. Publications: 21.
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
ClinicalTrials.gov study NCT01440101. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT00390221. IPD Sharing: Not stated. Countries: 8. Publications: 2.
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
ClinicalTrials.gov study NCT05123703. IPD Sharing: YES. Countries: 25. Publications: 1.
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT00803049. IPD Sharing: Not stated. Countries: 21. Publications: 4.
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT01497262. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Twin pregnancy outcome following teriflunomide treatment in a relapsing-remitting multiple sclerosis patient
<p>Teriflunomide is a disease-modifying drug that has been approved for treatment of relapsing-remitting multiple sclerosis. Due to its teratogenic effect in animals, however, it is not recommended during pregnancy. For this reason, effective contraception must be used during its administration. When an unscheduled pregnancy occurs during therapy, patients must undergo a cholestyramine procedure for rapid flushing of the drug. We describe the case of a 35-year-old female patient suffering diagnosed with relapsing-remitting multiple sclerosis at the age of 20. The patient as a result of side effects of previous therapies started taking teriflunomide. Despite recommendations for the use of contraceptives, the patient became pregnant during drug therapy. Pregnancy occurred 12 months after initiating teriflunomide treatment. Therapy with teriflunomide was immediately suspended and cholestyramine was prescribed (8 g 3 times a day, for 11 days) to flush out any residual drug from the body. Despite an 8-week exposure to teriflumomide during gestation, the patient gave birth to healthy twin girls at 35<sup>th</sup> week. Controls carried out after birth did not reveal any malformation or genetic and chromosomal abnormality. At a 5-month pediatric specialist check both babies were healthy and growing regularly. This shows that even if there is evidence of teratogenic effects in animals, an 8-week exposure to teraflunomide >0.02 mg/L did not have effects on the newborn.</p>
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT01701856. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT00645749. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)
ClinicalTrials.gov study NCT00395317. IPD Sharing: Not stated. Countries: 14. Publications: 1.
A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT01538355. IPD Sharing: Not stated. Countries: 1. Publications: 6.
A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
ClinicalTrials.gov study NCT05335031. IPD Sharing: NO. Countries: 1. Publications: 1.
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
ClinicalTrials.gov study NCT00525668. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT04009005. IPD Sharing: NO. Countries: 1. Publications: 11.
E-reporting of Adverse Drug Reactions by Patients in Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT03029897. IPD Sharing: NO. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.